Longfellow Investment Management Co. LLC Sells 127,573 Shares of Bristol Myers Squibb Company (NYSE:BMY)

Longfellow Investment Management Co. LLC lessened its holdings in shares of Bristol Myers Squibb Company (NYSE:BMY) by 85.9% during the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 20,945 shares of the biopharmaceutical company’s stock after selling 127,573 shares during the period. Longfellow Investment Management Co. LLC’s holdings in Bristol Myers Squibb were worth $1,277,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Pinney & Scofield Inc. bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $25,000. Park Square Financial Group LLC bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $26,000. Global Wealth Strategies & Associates grew its holdings in shares of Bristol Myers Squibb by 137.5% during the first quarter. Global Wealth Strategies & Associates now owns 475 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 275 shares during the last quarter. Transce3nd LLC bought a new stake in shares of Bristol Myers Squibb during the fourth quarter worth $28,000. Finally, Harel Insurance Investments & Financial Services Ltd. bought a new stake in shares of Bristol Myers Squibb during the first quarter worth $31,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Up 1.3%

NYSE:BMY opened at $45.96 on Monday. The company has a debt-to-equity ratio of 2.54, a quick ratio of 1.11 and a current ratio of 1.21. The company has a market cap of $93.55 billion, a PE ratio of 18.53, a PEG ratio of 2.35 and a beta of 0.36. Bristol Myers Squibb Company has a 52-week low of $42.96 and a 52-week high of $63.33. The stock has a 50-day simple moving average of $47.32 and a 200 day simple moving average of $51.82.

Bristol Myers Squibb (NYSE:BMY) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion during the quarter, compared to the consensus estimate of $11.32 billion. Bristol Myers Squibb had a return on equity of 80.04% and a net margin of 10.58%. Bristol Myers Squibb’s quarterly revenue was up .6% on a year-over-year basis. During the same period last year, the company earned $2.07 earnings per share. On average, sell-side analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 1st. Shareholders of record on Thursday, July 3rd were paid a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a yield of 5.4%. The ex-dividend date was Thursday, July 3rd. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 100.00%.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on BMY shares. Citigroup decreased their price target on Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating on the stock in a report on Friday, August 1st. Daiwa America lowered Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 5th. Piper Sandler started coverage on Bristol Myers Squibb in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $65.00 target price on the stock. Morgan Stanley reissued a “hold” rating on shares of Bristol Myers Squibb in a research note on Thursday, July 31st. Finally, Daiwa Capital Markets lowered Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 target price on the stock. in a research note on Tuesday, August 5th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $56.38.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.